Valneva SE (VALN) Total Current Liabilities (2020 - 2026)
Valneva SE's (VALN) quarterly Total Current Liabilities came in at $110.3 million in Q1 2026, down 1.26% year-on-year from $111.7 million in Q1 2025, and up 1.53% quarter-over-quarter from $108.6 million in Q4 2025.
Valneva SE (VALN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Total Current Liabilities across 7 years of filings, most recently posting $110.3 million for Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $110.3 million, down 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.3 million (down 1.26% YoY), and the FY2025 annual result was $108.6 million, down 11.27% from the prior year.
- Total Current Liabilities came in at $110.3 million for Q1 2026 at Valneva SE, up from $108.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $465.4 million in Q2 2022 to a low of $108.6 million in Q4 2025.
- The 5-year median for Total Current Liabilities is $170.9 million (2023), against an average of $212.6 million.
- Across the five-year window, Total Current Liabilities plunged 57.95% in 2024 and soared 46.75% in 2025, its largest moves.
- Valneva SE's Total Current Liabilities stood at $283.0 million in 2022, then sank by 39.6% to $170.9 million in 2023, then fell by 28.37% to $122.4 million in 2024, then dropped by 11.27% to $108.6 million in 2025, then grew by 1.53% to $110.3 million in 2026.
- The last three Total Current Liabilities figures came in at $110.3 million (Q1 2026), $108.6 million (Q4 2025), and $175.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 13.42 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 72.86 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 110.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110.31 Mn |
| Dec 31, 2025 | 108.64 Mn |
| Sep 30, 2025 | 175.92 Mn |
| Jun 30, 2025 | 142.24 Mn |
| Mar 31, 2025 | 111.71 Mn |
| Dec 31, 2024 | 122.44 Mn |
| Sep 30, 2024 | 119.88 Mn |
| Jun 30, 2024 | 110.37 Mn |
| Mar 31, 2024 | 126.11 Mn |
| Dec 31, 2023 | 170.93 Mn |
| Sep 30, 2023 | 237.48 Mn |
| Jun 30, 2023 | 262.48 Mn |
| Mar 31, 2023 | 282.57 Mn |
| Dec 31, 2022 | 283.01 Mn |
| Sep 30, 2022 | 377.31 Mn |
| Jun 30, 2022 | 465.37 Mn |
| Mar 31, 2022 | 407.70 Mn |
| Dec 31, 2021 | 422.10 Mn |
| Dec 31, 2020 | 209.69 Mn |